Jun 14 |
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
|
Jun 6 |
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
|
Jun 3 |
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
|
May 29 |
Zura Bio Announces Participation in June Investor Conferences
|
May 24 |
Zura Bio files to sell 41.6M Class A ordinary shares for holders
|
May 10 |
Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments
|
May 9 |
Zura Bio reports Q1 results
|
May 9 |
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
Apr 25 |
Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)
|
Apr 18 |
Zura Bio stock jumps on plans to raise $112.5M in private financing
|